p53 inactivation is often observed in Burkitt's lymphoma (BL) cells, because of either mutations in p53 gene or an overexpression of the p53-negative regulator MDM2. Epstein-Barr virus (EBV) is present in virtually 100% of BL cases occurring in endemic areas, but in only 10-20% of sporadic cases. In EBV(À) BL cells, reactivation of p53, induced by reducing MDM2 protein level, led to apoptosis. We show here that nutlin-3, a potent antagonist of MDM2, activates the p53 pathway in all BL cell lines harboring wild-type p53, regardless of EBV status. However, nutlin-3 strongly induced apoptosis in EBV(À) or latency I EBV( þ ) cells, whereas latency III EBV( þ ) cells were much more resistant. Prior treatment with sublethal doses of nutlin-3 sensitizes EBV(À) or latency I EBV( þ ) cells to apoptosis induced by etoposide or melphalan, but protects latency III EBV( þ ) cells. p21 WAF1 which is overexpressed in the latter, is involved in this protective effect, as siRNA-mediated inhibition of p21 WAF1 restores sensitivity to etoposide. Nutlin-3 protects latency III BL cells by inducing a p21 WAF1 -mediated G1 arrest. Most BL patients with wild-type p53 tumors could therefore benefit from treatment with nutlin-3, after a careful determination of the latency pattern of EBV in infected patients.
Introduction
The p53 tumor suppressor is a transcription factor that is activated in response to DNA damage or cellular stress and regulates many target genes involved in controlling DNA repair, cell-cycle arrest and apoptosis. 1, 2 This physiological function of p53 is frequently altered in tumor cells through mutation, cytoplasmic sequestration, interaction with viral oncoproteins or increased interactions with its main cellular regulator, MDM2.
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MDM2 is a 90-kDa protein that binds to the NH 2 terminus of p53, blocking its transcriptional activities. It is also an E3-ubiquitin ligase involved in the ubiquitination of p53, leading to both proteasomal degradation and relocation of p53 from the nucleus to the cytoplasm. However, MDM2 is the product of a p53-inducible gene, so these two proteins constitute an autoregulatory feedback loop that plays an essential role in the activation of p53. 4, 5 The overexpression of MDM2, leading to p53 inactivation, has been observed in various types of cancer. [6] [7] [8] [9] Given the key role of p53 in determining cell fate, several strategies for disrupting the p53-MDM2 interaction have been explored. 10, 11 Recently, potent, stable and selective smallmolecule antagonists of MDM2 have been synthesized. Among these molecules, nutlins are cis-imidazoline compounds that bind to MDM2, thereby preventing its molecular interaction with p53 and inducing activation of the p53 pathway. 12 Nutlin-3 has been shown to trigger apoptosis in various tumor cells in vitro, 13, 14 to inhibit tumor growth in vivo 12 and to synergize with genotoxic drugs (such as alkylating agents or topoisomerase II inhibitors) and irradiation in cancer therapy. [15] [16] [17] [18] [19] [20] Burkitt's lymphoma (BL) is a monoclonal B-cell tumor characterized by chromosomal translocations affecting the proto-oncogene c-myc locus and the immunoglobulin (Ig) heavy or light chain genes, thereby leading to deregulation of c-myc. In addition, most BL cell lines and at least 30% of BL biopsy samples display p53 mutations, resulting in the inactivation of this gene. 21 We and others earlier investigated the status of MDM2 and p53 in BL cell lines or biopsy samples and found that, in several cases containing wild-type (wt) p53, the function of this protein was compromised by the overexpression of MDM2. 8, 22 Finally, another study has shown that p14 ARF , which regulates the function of p53, is frequently altered in BL cell lines carrying wt p53. 23 All these data clearly demonstrate that disruption of the p53 pathway contributes to BL development. 24, 25 They also suggest that the restoration of wt p53 function in BL cells may be an efficient treatment strategy, at least in patients with cancers resistant to standard chemotherapy treatments. Using anti sense (AS) oligodeoxynucleotides, we showed earlier that AS against MDM2 indeed induced p53-dependent apoptosis in BL cells containing wt p53 and large amounts of MDM2. 26 The aim of this study was to investigate further the consequences of activating wt p53 in BL cell lines and to determine whether Epstein-Barr virus (EBV) infection of these cells had any effect on these consequences. Indeed, the EBV genome is present in more than 95% of endemic BL cases (in Equatorial Africa and Papua New Guinea) and in 10-20% of all sporadic cases worldwide. The viral infection remains latent in tumor cells, with only a very small number of viral proteins produced. 27 Most EBV-infected BL cells have the latency I phenotype (Epstein-Barr nuclear antigen 1 (EBNA1) is the only viral protein produced). However, cases with the latency III profile (all latent EBV proteins are produced: EBNA1, 2, 3a, 3b, 3c, Epstein-Barr nuclear antigen-leader protein (EBNA-LP), latent membrane protein 1 (LMP1) and LMP2)) or with unusual forms of latency have also been identified. 28, 29 Latent EBV does not specifically target p53, but it nonetheless interferes with cell-cycle checkpoints regulated by p53 in the G1/S and G2/M phases 30, 31 and modulates p53-induced apoptosis. 32 We show here that, regardless of EBV status, the treatment of BL cells with nutlin-3 induces p53 activation. However, we also show that induction of apoptosis or sensitization to genotoxic drugs by nutlin-3 is clearly different between EBV(À) or EBV( þ ) latency I BL cells and EBV( þ ) latency III cells. 
Materials and methods

Cell lines
Induction of apoptosis and its quantification
We treated 0.5 Â 10 6 cells for various periods of time at 37 1C with nutlin-3 (2 or 10 mM), etoposide (2.5 or 10 mM) or melphalan (12.5 mM) in 1 ml of complete RPMI medium. Cells were washed in PBS, resuspended in annexin buffer (10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)/NaOH, pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl 2 and 1.8 mM CaCl 2 ) supplemented with 2.5 mg/ml FITC-labeled annexin-V (Roche Applied Science, Meylan, France) and incubated at 4 1C for 10 min. Cells were then washed, resuspended in annexin buffer supplemented with propidium iodide (PI) (10 mg/ml) and analyzed by flow cytometry (FACSCalibur, Becton-Dickinson, Le Pont de Claix, France).
Cell-cycle analysis
Cells were fixed by incubating in 70% ethanol at -20 1C for at least 30 min, washed twice in PBS and incubated for 30 min at 37 1C in 20 mM EDTA, 100 mg/ml RNase A (Sigma-Aldrich) and 10 mg/ml PI in PBS. DNA content was determined by flow cytometry.
Western-blot analysis
A pellet containing 0.5 Â 10 6 cells was solubilized by incubating in ice-cold lysis buffer (25 mM Tris-HCl, pH 6.8, 1% SDS, 50 mM dithiothreitol and complete protease inhibitor) for 10 min. Sample loading buffer was added and the mixture was boiled for 5 min. Proteins were separated by electrophoresis in 12% polyacrylamide gels or 4-12% Bis-Tris precast gels (Invitrogen) and then transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Molsheim, France). Blots were blocked by incubation overnight at 4 1C in 3% non-fat milk powder, 2% glycine in PBS and incubated for 1 h at room temperature with primary antibodies. The blots were washed and incubated with horseradish peroxidase (HRP)-conjugated rabbit anti-mouse (RAM)-IgG or HRP-conjugated donkey antirabbit (DAR)-IgG. Antibody complexes were detected by enhanced chemiluminescence (Millipore).
Results
Nutlin-3 induces high levels of apoptosis in EBV(À) or EBV( þ ) latency I BL cells and moderate levels in EBV( þ ) latency III cells
As we aimed to determine whether the EBV status of BL cells played a role in their fate following p53 activation, we first assessed the levels of various latent EBV proteins in six cell lines containing wt p53. 8 Western-blot analysis of protein extracts showed that BL2 and BL28 cells contained none of the EBNA proteins tested, BL7 contained only EBNA1, whereas BL2/B95, LY47 and Seraphina contained different isoforms of EBNA1, EBNA2 and EBNA-LP ( Figure 1a ). These results confirmed that BL2 and BL28 cells were EBV(À), 33 and indicated that BL7 cells displayed type I latency, whereas BL2/B95, LY47 and Seraphina cells displayed type III latency. These cell lines, together with the EBV(À) Ramos and EBV( þ ) P3HR1 cell lines, both of which carrying a mutant p53 gene, were then treated with nutlin-3 (10 mM) for 24 h and apoptosis was assessed (by flow cytometry, after labeling the cells with annexin-V-FITC and PI). As shown in Figure 1b , BL2, BL28 and BL7 were highly sensitive to nutlin-3 treatment (93 ± 4, 100 ± 0 and 89 ± 1% apoptotic cells, respectively), whereas BL2/B95, Seraphina and LY47 were more resistant (28 ± 1, 27 ± 4 and 39 ± 7% apoptotic cells, respectively). As expected, Ramos and P3HR1 were totally resistant to nutlin-3 treatment.
Nutlin-3 activates the p53 pathway similarly in all BL cell lines
The differences observed in the apoptotic responses of BL cells carrying wt p53 and having different EBV status raised questions as to whether nutlin-3 activates p53 similarly in all these cell lines. We treated the six BL cell lines with nutlin-3 for various periods of time and then carried out western blotting to determine the levels of p53, p21 WAF1 , MDM2 and Bax, the last three of these proteins being encoded by p53 target genes ( Figure 1c) . Specific bands were then quantified by densitometric analysis and normalized to b-actin level. Protein levels after 3, 7 and 24 h of treatment relative to levels before treatment are shown in Supplementary Figure 1 . In all BL cell lines, 3 h of treatment with nutlin-3 induced the accumulation of p53, which then either remained stable or gradually increased (except in BL28, in which p53 level decreased after 24 h). Treatment with nutlin-3 for 3 or 7 h induced an increase in MDM2 levels, followed by a decrease in all cell lines except in Ly47 (in which MDM2 level remained high). The ability of MDM2 to ubiquitinate itself and induce its own degradation 4 is probably responsible for this decrease in MDM2 levels. p21
WAF1 protein accumulated in all cell lines after 3 and 7 h of treatment with nutlin-3 and then decreased (BL28), remained stable (BL2, BL7and BL2/B95) or increased (Seraphina and Ly47). In all BL cell lines, treatment with nutlin-3 induced a slower, but gradual increase in Bax levels until 24 h of treatment. This observation of a slower induction of Bax by p53, as compared with p21
WAF1
Nutlin and drug-induced apoptosis in BL cells B Renouf et al and MDM2, is in agreement with earlier results. 34 Altogether these results indicate that activation of the p53 pathway is not correlated with the EBV status of the cells.
Nutlin-3 increases drug-induced apoptosis in EBV(À) and EBV( þ ) latency I BL cells, but protects EBV( þ ) latency III cells
Synergistic effects of nutlin-3 and chemotherapeutic agents have been reported in various types of cancer with functional wt p53. [16] [17] [18] We therefore treated the BL cell lines with etoposide, with and without prior nutlin treatment. In order to compare the three types of BL cells, they were treated with a dose of nutlin-3 (2 mM), sublethal for all cell lines, but which, however, induced p53 activation (data not shown). After this initial treatment for 24 h, the cells were incubated for various periods of time (7, 24 and 48 h) with etoposide. Apoptosis levels were determined by assessing the cleavage of polyadenosine diphosphate ribose polymerase (PARP) by western blots (Figure 2 upper panel) . EBV(À) BL2 and EBV( þ ) latency I BL7 cells were highly sensitive to 7 and 24 h of treatment with etoposide alone and prior treatment with nutlin-3 slightly increased the effect of this drug. Latency III cells were less sensitive to etoposide than EBV(À) or latency I cells and were thus treated for longer periods of time (24 and 48 h), and for Seraphina and LY47 cells with higher doses of etoposide (10 mM instead of 2.5 mM). After 24 and 48 h of treatment with etoposide alone, the 85-kDa PARP cleavage product was detected in the protein extracts. Surprisingly, the pre-treatment of latency III cells with nutlin-3 did not sensitize these cells to etoposide-induced apoptosis. Instead, such prior treatment significantly protected the cells against apoptosis: PARP cleavage either occurred at much lower rates than in the absence of prior treatment or was not detectable. These differential effects of prior treatment with nutlin-3 on etoposide-induced apoptosis were then confirmed by quantifying apoptosis by flow cytometry analysis of the BL cells labeled with annexin-V-FITC and PI (Supplementary Figure 2) .
We also investigated the effect of prior treatment with nutlin-3 on melphalan-induced apoptosis of BL cells. Apoptosis levels were determined by assessing PARP cleavage on western blots (Figure 2 lower panel) . In EBV(À) BL2 and EBV( þ ) latency I BL7 cells, treatment with nutlin-3 did not induce PARP cleavage, but prior treatment with this compound strongly increased PARP cleavage induced by 7 h of treatment with melphalan. In contrast, prior treatment with nutlin-3 of latency III BL2/B95, Seraphina and LY47 cells reduced PARP cleavage induced by melphalan. Thus, in EBV( þ ) latency III BL cells, nutlin-3 and chemotherapeutic drugs did not synergize to induce apoptosis. Instead, nutlin-3 protected these tumor cells from drug-induced apoptosis.
Nutlin-3 induces cell-cycle arrest in EBV( þ ) latency III BL cells, but not in EBV(À) or latency I BL cells
p21
WAF1 protein, a cyclin-dependent kinase inhibitor, is a key regulator of the cell cycle and is also known to interfere with both p53-dependent and p53-independent apoptotic pathways. 35, 36 We therefore investigated the role of this protein in our model of drug-induced apoptosis. We first compared basal levels of p21 WAF1 protein in the various BL cell lines. Latency III cells (BL2/B95, Seraphina and LY47) contained very large amounts of p21 WAF1 , whereas EBV(À) and latency I cells (BL2 and BL7) had very low levels of this protein (Figure 3a) . We then analyzed the effect of nutlin-3 treatment (at the sublethal dose of 2 mM) on cell-cycle progression of the various BL cells. As shown in Figure 3b , treatment with nutlin-3 for 24 h had almost no effect on EBV(À) BL2 and latency I BL7 cells (other than a slight increase in the number of sub-G1 apoptotic cells for BL2). By contrast, comparison of untreated and treated cells clearly shows that nutlin-3 induced the accumulation of latency III BL cells in G1 phase (78% vs 49% for BL2/B95, 76% vs 58% for Seraphina and 62% vs 50% for LY47). Thus, in EBV( þ ) latency III BL cells, which express high amount of p21 WAF1 protein, low doses of nutlin-3 induce cell-cycle arrest in G1 phase.
Etoposide resistance conferred by nutlin-3 pre-treatment depends on p21 WAF1 protein level and on induction of cell-cycle arrest
We next investigated the role of the p21 WAF1 protein in the protection against drug-induced apoptosis, generated in latency III BL cells by prior treatment with nutlin-3. To this end, we used cells in which p21 WAF1 expression had been inhibited by a specific siRNA. The cells were first electroporated with p21 WAF1 siRNA or control siRNA; 24 h later, cells were or were not treated with nutlin-3 for 24 h, and all cells were then treated with etoposide (2.5 or 10 mM) for 24 h. Apoptosis levels were determined by quantifying PARP cleavage on western blots (Figure 4a) . In all latency III BL cells electroporated with control siRNA, etoposide treatment alone induced PARP cleavage and prior treatment with nutlin-3 gave complete protection against etoposide. The inhibition of p21 WAF1 expression with a specific Western blots for p21 WAF1 confirmed that the p21 WAF1 siRNA efficiently inhibited the expression of this protein, even when its level was increased following activation of p53 by nutlin-3 treatment (Figure 4a) . Altogether, our data indicate that BL cells with low levels of p21 WAF1 (BL2, BL7 and p21 WAF1 siRNAtreated latency III cells) are more sensitive to drug-induced apoptosis than cells with high levels of p21 WAF1 (latency III cells) and also that, in these latter cells, nutlin-3 further enhances their resistance by increasing the level of p21 WAF1 . We then determined whether the increased resistance to drugs, induced in the latency III BL cells by nutlin-3, is related to the ability of this compound to induce cell-cycle arrest. Seraphina cells were electroporated with p21 WAF1 siRNA or control siRNA and 24 h later, cells were or were not treated with nutlin-3 for another 24 h. Cells were then treated or not with etoposide for 48 h and the cell cycle was analyzed. The percentages of cells in G1 phase and in sub-G1 phase (apoptotic cells) are shown in Figure 4b . Prior treatment with nutlin-3 of cells electroporated with control siRNA induced a strong G1 arrest (81%), which persisted after etoposide treatment (74%). In these nutlin-3 pre-treated cells, etoposide induced a low level of apoptosis as compared with non-pre-treated cells (20% vs 53% of cells in sub-G1). By contrast, pre-treatment with nutlin-3 of cells with low levels of p21 WAF1 (cells electroporated with p21 WAF1 siRNA) induced a lower G1 arrest (68%) and this arrest was not maintained after etoposide treatment (30%). These nutlin-3 pre-treated cells entered apoptosis (58%) similar to nonpre-treated cells (65%). Together with the previous cell-cycle data, these results indicate that the p21 WAF1 -mediated G1 arrest induced by nutlin-3 in latency III BL cells is responsible for the protective effect of this compound against drug-induced apoptosis. They also show that this protection highly depends on the high basal level of p21 WAF1 protein in the cells.
A cyclin-dependent kinase inhibitor protects latency III BL cells from etoposide-induced apoptosis p21 WAF1 induces cell-cycle arrest by interacting with and inhibiting cyclin-cdk complexes, especially those containing Cdk2. We thus assessed the effect of a pharmacological inhibitor of Cdk2 on etoposide-induced apoptosis of latency III BL cells. Cells were treated for 24 h with an inhibitor of Cdk2 (Cdk2i) and then with etoposide for 24 and 48 h. Apoptosis was measured by flow cytometry after labeling the cells with annexin-V-FITC and PI (Supplementary Figure 3) and by assessing PARP cleavage on western blots ( Figure 5 ). For LY47 cells, prior treatment with Cdk2i induced only a slight protection in cells treated with etoposide (mostly after 48 h), but for BL2/B95 and Seraphina cells, prior treatment with Cdk2i clearly induced resistance to etoposide. Indeed, in these cells, reduced numbers of apoptotic cells and decreased amounts of the 85-kDa cleaved PARP were observed after 24 and 48 h of treatment with etoposide, as compared with non-pre-treated cells. These results, showing that treatment with a specific inhibitor of Cdk2 protects latency III BL cells against drug-induced apoptosis, support our conclusion concerning the protective action of nutlin-3 through cell-cycle arrest.
Discussion
We showed that nutlin-3, a specific inhibitor of the p53-MDM2 interaction, stabilized and activated p53 in all BL cells containing wt p53. However, we also showed that the level of apoptosis induced by nutlin-3-mediated p53 activation depended on the EBV status of the cells. Nutlin-3 has been shown to synergize Nutlin and drug-induced apoptosis in BL cells B Renouf et al with genotoxic drugs or radiation in several types of tumor cells containing wt p53. [16] [17] [18] [19] [20] We therefore investigated the effects of nutlin-3 in combination with various chemotherapeutic drugs, and showed that nutlin-3 sensitized EBV(À) or latency I EBV( þ ) BL cells to these drugs, but protected latency III EBV( þ ) cells against their effects. We also found that the siRNAmediated inhibition of p21 WAF1 decreased the protection to drug-induced apoptosis conferred by treatment with nutlin-3. Finally, we showed that the ability of p21 WAF1 to arrest latency III EBV( þ ) cells in the G1 phase of the cell cycle after treatment with nutlin-3 was responsible for the protective effect of this compound.
The anti-tumoral action of nutlin-3 and its synergistic effects with various types of drugs or radiation have been amply demonstrated by both in vitro studies on human cells and in vivo studies in animal models. 37 As p53 is rarely mutated in hematologic malignancies, many studies have been carried out on various types of tumor cell, including chronic lymphocytic leukemia B cells (B-CLL), 18, 20 myeloma, 14 Kaposi sarcoma herpes virus (KHSV)-induced lymphoma 13, 38 and Hodgkin's lymphoma. 19 In some cases, nutlin-3 is also able to induce apoptosis in p53-inactivated cells through a p73-dependent mechanism 39 and, as shown recently in a mantle cell lymphoma cell line carrying mutated p53, to synergize with drugs. 40 All these studies have suggested that nutlin-3 may indeed be considered, alone or in combination with various genotoxic drugs, as a novel therapeutic approach for patients. We show here that this approach could also be considered for patients with BL, at least for those who are not infected with EBV. For EBV( þ ) latency I BL cells, more samples would need to be tested before considering to use such treatments. However, it is interesting to note that recent reports on primary effusion lymphoma (PEL) cells treated with nutlin-3 are in line with our results. 13, 38 PEL cells are always infected with a transforming human g herpes virus (HHV) called Kaposi's sarcoma herpes virus (KSHV/HHV8) and often co-infected with EBV. 41 These cells, which have a latency I phenotype, as well as EBV(À) PEL cells are very sensitive to nutlin-3-induced apoptosis.
Our data also showed that nutlin-3 had different cytotoxic properties in different cells. In particular, this compound may sensitize cells to chemotherapy or, on the contrary, partially protect tumor cells from chemotherapy. Other studies have reported protective effects of nutlin-3 against drugs. For example, nutlin-3 has been reported to have a p53-independent cytoprotective effect: the treatment of normal kidney with nutlin-3 blocks Bax and Bak activation, abolishing the apoptosis induced by cisplatin. 42 However, it has also been suggested that the cell-cycle arrest function of p53 induced by nutlin-3 could be used to eliminate unwanted side effects of chemotherapy in patients with cancer cells expressing a mutant p53. The treatment of normal human fibroblasts (or tumor cells containing wt p53) with nutlin-3 has been shown to induce cell-cycle arrest, protecting these cells against the effects of mitotic inhibitors or S-phase-specific chemotherapy. By contrast, prior treatment with nutlin-3 did not prevent tumor cells containing mutant p53 from undergoing apoptosis after chemotherapy of this type, because the cells were not blocked in the G1-or G2-phases. 43, 44 These data highlight the importance of identifying patients with tumors containing both wt p53 and a preserved downstream p53 apoptotic signaling before treatment.
Our results demonstrate a previously unknown aspect of the anti-tumor potential of nutlin-3 combined with drug treatment. Indeed, we showed that functional p21 WAF1 protein levels may be considered as an indicator of nutlin-3 efficiency. In cells with very high basal levels of p21 WAF1 , nutlin-3 treatment increased p21 WAF1 levels further, resulting in a strong G1-phase arrest and a decrease in the number of cells undergoing genotoxic druginduced apoptosis. p21 WAF1 has been described as a negative regulator of p53-dependent apoptosis. For example, p21 WAF1 overexpression has been shown to protect osteosarcoma cells from etoposide treatment 45 and p21 WAF1 -null tumor cells have been reported to undergo apoptosis after treatment with doxorubicin, whereas cells with intact or transfected p21 WAF1 do not. 46, 47 In BL cells, the intrinsically low sensitivity of EBV( þ ) latency III cells to etoposide and melphalan (see Figure 2) is probably, at least partly, because of the high levels of p21 WAF1 in these cells. The precise role of EBV in the p21 WAF1 overexpression and differential sensitivity of cells remains to be determined. The EBNA2 viral protein has been shown to induce p21 WAF1 production in various types of cell. 48 It, therefore, could be hypothesized that EBNA2 is involved in the resistance of latency III BL cells to drugs. However, other studies have shown that lymphoblastoid cell lines (LCLs) and EBV-infected primary B cells, both of which have a latency III phenotype (and therefore produce EBNA2), undergo apoptosis in response to various DNA-damaging agents. 30, 49, 50 These studies also reported that p53 is activated, but newly synthesized p21 WAF1 does not accumulate in treated cells. In accordance with these observations, we recently obtained preliminary data showing that, in contrast to what has been observed in latency III BL cells, the treatment of various lymphoblastoid cell lines (LCLs) (that also have high basal levels of p21 WAF1 ) with nutlin-3, rather than protecting cells against etoposide, actually had a synergistic effect with this drug in the induction of apoptosis. Our results therefore indicate that p21 WAF1 -mediated inhibition of druginduced apoptosis in cells containing wt p53 is dependent on a certain specific cellular context.
